Research Papers:
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth
Metrics: PDF 1397 views | HTML 2002 views | ?
Abstract
Xin Chen1,*, Yuanyuan Hu2,*, Shuo Wang1, Xiulian Sun2
1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P. R. China; China National Clinical Research Center for Neurological Diseases, Beijing, P. R. China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, P. R. China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, P. R. China
2Brain Research Institute, Qilu Hospital of Shandong University, Jinan, Shandong Province, China
*These authors have contributed equally to this work
Correspondence to:
Xiulian Sun, email: [email protected]
Shuo Wang, email: [email protected]
Keywords: RCAN1, suppress, apoptosis, glioma, NF-κB signaling
Received: September 26, 2016 Accepted: December 20, 2016 Published: January 04, 2017
ABSTRACT
Nuclear factor-kappaB (NF-κB) has a vital role in cell survival and inhibition of NF-κB had proven to be an efficient therapeutic pathway for various cancers though little is known about the underlying mechanism. Previously we identified regulator of calcineurin 1 (RCAN1) as an endogenous inhibitor of NF-κB signaling pathway in lymphoma. In the present study, we have solid data to show that RCAN1 can inhibit the nuclear translocation of NF-κB protein then affect the activity of NF-κB signaling pathway in glioma cells. Overexpression of RCAN1 markedly reduced glioma cells viability. We further found that the suppressing glioma cell growth was closely related to the pro-apoptosis effect, not by inhibiting proliferation by the arrest of cell cycle. Our study implicated a novel therapeutic approach for glioma by RCAN1 through inhibition of NF-κB signaling.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14479